ZA933023B - The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds. - Google Patents

The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds.

Info

Publication number
ZA933023B
ZA933023B ZA933023A ZA933023A ZA933023B ZA 933023 B ZA933023 B ZA 933023B ZA 933023 A ZA933023 A ZA 933023A ZA 933023 A ZA933023 A ZA 933023A ZA 933023 B ZA933023 B ZA 933023B
Authority
ZA
South Africa
Prior art keywords
inflammations
wounds
inhibitors
treatment
plasminogen activators
Prior art date
Application number
ZA933023A
Inventor
Eckhard Schueler
Juergen Roemisch
Eric-Paul Pâques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of ZA933023B publication Critical patent/ZA933023B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA933023A 1992-04-30 1993-04-29 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds. ZA933023B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (en) 1992-04-30 1992-04-30 USE OF INHIBITORS OF PLASMINOGEN ACTIVATORS FOR TREATING INFLAMMATION

Publications (1)

Publication Number Publication Date
ZA933023B true ZA933023B (en) 1994-10-31

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA933023A ZA933023B (en) 1992-04-30 1993-04-29 The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds.

Country Status (16)

Country Link
EP (1) EP0567816A1 (en)
JP (1) JPH069425A (en)
KR (1) KR930021179A (en)
CN (1) CN1080873A (en)
AU (1) AU3822993A (en)
CA (1) CA2095207A1 (en)
CZ (1) CZ76893A3 (en)
DE (1) DE4214215A1 (en)
HU (1) HUT65755A (en)
IL (1) IL105521A0 (en)
MX (1) MX9302519A (en)
NO (1) NO931561L (en)
PL (1) PL298748A1 (en)
SK (1) SK41593A3 (en)
UY (1) UY23572A1 (en)
ZA (1) ZA933023B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
ATE339975T1 (en) * 1993-07-19 2006-10-15 Angiotech Pharm Inc ANTI-ANGIOGENIC STENT AND METHOD FOR THE PRODUCTION THEREOF
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
KR20010042402A (en) * 1998-04-01 2001-05-25 로잘란드 앤 칼도르 Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
MXPA01011025A (en) 1999-04-29 2002-11-07 Ista Pharmaceuticals Inc Biochemical methods that eliminate corneal scars, opacification and haze.
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (en) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション Client server system, object pooling method, and storage medium
ATE297217T1 (en) 1999-10-27 2005-06-15 Alexandra Lucas COMPOSITION FOR PREVENTING AND TREATING TRANSPLANT REJECTION
JP2001247458A (en) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd Therapeutic agent for diabetes comprising zinc tranexmate compound
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
EP1582180B1 (en) 2000-10-16 2008-02-27 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (en) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm USE IN VITRO OF THE TRANSCRIPTION FACTOR NAK-1 OR NAK-1 REGULATED GENES FOR THE DIAGNOSIS OF INFLAMMATORY AND MALIGNIC DISEASES
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2009093119A2 (en) * 2008-01-21 2009-07-30 Med Discovery S.A. Use of serine protease inhibitors in the treatment of skin diseases
TWI763960B (en) * 2017-12-15 2022-05-11 大陸商深圳瑞健生命科學研究院有限公司 Method and medicine for preventing or treating osteoarthritis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (en) * 1988-08-31 1990-03-01 Behringwerke Ag USE OF PLASMINOGEN ACTIVATOR INHIBITOR (PAI-2) FOR IMMUNE SUPPRESSION
US5444153A (en) * 1989-12-20 1995-08-22 Biotech Australia Pty Limited Variants of PAI-2
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
UY23572A1 (en) 1993-05-04
CN1080873A (en) 1994-01-19
DE4214215A1 (en) 1993-11-04
EP0567816A1 (en) 1993-11-03
AU3822993A (en) 1993-11-04
MX9302519A (en) 1993-10-01
JPH069425A (en) 1994-01-18
HU9301272D0 (en) 1993-07-28
NO931561L (en) 1993-11-01
HUT65755A (en) 1994-07-28
PL298748A1 (en) 1993-12-27
CZ76893A3 (en) 1994-01-19
NO931561D0 (en) 1993-04-29
CA2095207A1 (en) 1993-10-31
IL105521A0 (en) 1993-08-18
KR930021179A (en) 1993-11-22
SK41593A3 (en) 1993-11-10

Similar Documents

Publication Publication Date Title
ZA933023B (en) The use of inhibitors of plasminogen activators for the treatment of inflammations and wounds.
AU5590596A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
AU2956492A (en) Antibacterial agent and treatment of article therewith
EP0622063A3 (en) Disposable absorbent articles and methods of making same.
AU4859793A (en) Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
EP0594410A3 (en) Treatment of rubber articles.
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU3107795A (en) Inhibitors of the benzamidine type
AU4069095A (en) Medicaments for the treatment of restenosis and arterial sclerosis
AU3099997A (en) The use of tcet in the prophylaxis and treatment of allergies
ZA935575B (en) Therapeutic agent and its use.
IL108098A0 (en) Inhibitors of hiv protease useful for the treatment of aids
IL105973A0 (en) Inhibitors of hiv protease useful for the treatment of aids
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
EP0674707A4 (en) Compounds and methods for the treatment of leukemias.
GB9409336D0 (en) Use of an enzyme for manufacturing an agent for the treatment and/or prophylaxis of coccidiosis
GB2267089B (en) Cycloheptimidazole derivatives,method of manufacturing the same and therapeutic agents containing these compounds
AU1870292A (en) Use of neutral endopeptidase inhibitors in the treatment of nephrotoxicity
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
GB9317943D0 (en) Treatment of laminitis
AU4825993A (en) New compounds for use in the treatment of cancer
AU612562B2 (en) A composition comprising a plasmin inhibitor and a plasminogen activator for the treatment of thrombosis
ZA929143B (en) Agents for use in the prophylaxis and therapy of fungal infections.